Calendar of Events

• American Society of Cataract and Refractive Surgery (ASCRS): Annual Meeting: April 19 – 23, 2013
• The Association for Research in Vision and Ophthalmology (ARVO): Annual Meeting: May 5 -9, 2013
• 5th World Glaucoma Congress (WGC): July 17-20, 2013
• European Society of Cataract and Refractive Surgeons (ESCRS): Annual Meeting: October 5 -9, 2013
• American Academy of Ophthalmology (AAO): Annual Meeting: November 16-19, 2013

Icon Bioscience, Inc. (IBI) is a privately held company focused on the development and commercialization of novel ophthalmic pharmaceuticals, based on its proprietary drug delivery platform, Verisome®.

IBI's Verisome® drug delivery technology is the most advanced, yet simplest system for controlling the release of intraocular therapeutic agents in the eye for extended periods of time. Its unmatched versatility can support products individually formulated to meet the specific clinical requirements of a given active agent targeting a specific ophthalmic disease.

IBI's current portfolio consists of seven (7) proprietary products, all targeting significant unmet ophthalmic medical needs. These include two (2) products at the clinical stage of development with two (2) more scheduled to begin human trials in 2013. Over 200 patients have been administered products based on the Verisome® drug delivery technology. IBI has also executed research agreements with multiple global pharmaceutical companies.

  • Icon’s Melphalan Intraocular Injection Granted U.S. Orphan Drug Status Designation for the Treatment of Retinoblastoma
13452978_s

  IBI-10090 will be Icon’s first product developed using the Verisome® technology to reach the market.  IBI-10090 is a biodegradable product for injection of dexamethasone into the anterior chamber to treat inflammation associated with cataract surgery. IBI-10090 is intended to be injected into the anterior chamber of the eye immediately after cataract surgery and safely deliver therapeutic levels of the active ingredient, dexamethasone.  It is designed to eliminate the need for … Read more

Icon Bioscience, Inc. will pursue corporate partnerships and out-licensing agreements of its Verisome® technology in limited opportunistic circumstances.  IBI is currently involved with multiple collaborations involving a wide variety of new chemical entities targeting various ophthalmic indications.  These collaborations involve small molecules and biologics … Read More

William S. (Sandy) White
Chief Executive Officer
1253 Reamwood Avenue
Sunnyvale, California 94089

United States

Tel: 408-492-9515

Icon Bioscience, Inc. | 1253 Reamwood Ave. | Sunnyvale, CA | 94089
Copyright © 2013 Icon Bioscience, Inc. · Optimization by MME · Log in